BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Doctors looking into hormone therapy as a way to ward off dementia in women - 2Philippines evacuates 3,000 villagers after volcano activity raises alert level
- 3CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- 41,000-mile Saharan dust storm, from the sky and from the ground
- 5Party Urban areas of the World
- You finally got a doctor's appointment. Here's how to get the most out of it
- The year's first meteor shower and supermoon clash in January skies
- This Week In Space podcast: Episode 189 — Privatizing Orbit
- Knesset sets special panel to fast-track Karhi’s communications reform
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- The 10 Most Noteworthy Games in History
- How do my eyes adjust to the dark and how long does it take?
- Interstellar comet 3I/ATLAS reveals weird wobbling jets in rare sun-facing tail
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
